Treatment of Liposarcoma in Myxoid Liposarcoma (MLS)

Clinical Scenario

Myxoid liposarcoma (MLS) is a recognised histological subtype of liposarcoma with a distinct treatment profile. Among soft tissue sarcoma subtypes, MLS is identified as one of the histological types that gains the greatest benefit from radiotherapy, making accurate subtype identification central to first-line treatment planning.

First-Line Treatment Approach

Management of myxoid liposarcoma is centred on surgical resection combined with radiotherapy. The radiotherapy component is particularly effective in this subtype. An alternative reduced radiotherapy regimen has demonstrated activity in MLS. Where neoadjuvant systemic therapy is selected for appropriate patients, established chemotherapy is used, with an alternative agent available as an option in this subtype.

Full regimen details, sequencing, dose schedule, and patient-selection criteria are in the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2021.07.006

Histological types such as MLS, solitary fibrous tumour (SFT), myxofibrosarcoma and extraskeletal myxoid chondrosarcoma gain the greatest benefit from RT.
For MLS, one study has recently investigated a low dose (18 × 2 Gy), showing activity of the reduced regimen, but without comparing the efficacy with conventional doses.
In MLS, data from one trial suggest that trabectedin may be an alternative to AI.

View source ↗